Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts.
Uwe PlatzbeckerValeria SantiniRami S KomrokjiAmer M ZeidanGuillermo Garcia ManeroRena BucksteinDimana MitevaKaren KeepermanNatalia HolotJose Alberto NadalYinzhi LaiSadanand VodalaBarbara RosettaniAna Carolina GiuseppiAylin YucelPierre FenauxPublished in: Leukemia (2023)